Clinical Trial Update: Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on AeroVanc for persistent MRSA lung infection in cystic fibrosis patients reports efficacy and safety findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• AeroVanc (telavancin? wait no; AeroVanc is an inhaled vancomycin formulation)

Snippet

Sponsor: Savara Inc. | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2020-01-13